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Abstract Recent studies of vascular adhesion protein-1
(VAP-1) have greatly advanced our understanding of the
important role this protein plays in the establishment and
progression of inflammatory disease. To facilitate more
detailed studies on the function of VAP-1, we developed a
GFP-fusion protein that enabled us to monitor the traf-
ficking of the protein in three selected cell types: hepatic
sinusoidal endothelial cells, liver myofibroblasts and an
hepatic stellate cell line (LX-2). The fusion protein was
detected as punctate cytoplasmic GFP staining, but was
present only at low levels at the cell surface in all cell types
studied. The subcellular distribution of the protein was not
altered in a catalytically inactive mutant form of the protein
(Tyr471Phe) or in the presence of exogenous VAP-1 sub-
strate (methylamine) or inhibitor (semicarbazide). The
GFP-VAP-1 protein was localized to the Golgi apparatus
(GM-130), endoplasmic reticulum (GRP94) and early en-
dosomes (EEA-1). Additional staining for VAP-1 revealed
that the overexpressed protein was also present in vesicles
that were negative for GFP fluorescent signal and did not
express EEA-1. We propose that these vesicles are
responsible for recycling the fusion protein and that the
fluorescence of the GFP moiety is quenched at the low pH
within these vesicles. This feature of the protein makes it
well suited for live cell imaging studies where we wish to
track protein that is being actively trafficked within the cell
in preference to that which is being recycled.
Keywords Vascular adhesion protein-1  Amine oxidase 
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Introduction
Vascular adhesion protein-1 (VAP-1, AOC3) is a trans-
membrane protein that is expressed in endothelial, adipose
and smooth muscle cells and has been shown to support the
recruitment of immune cells into sites of inflammation
through interactions with ligands, such as Siglec-9/Siglec-
10 or via deamination of primary amines (for recent
reviews see (Weston and Adams 2011; Salmi and Jalkanen
2011)).
The expression of VAP-1 in primary hepatic sinusoidal
endothelial cells is not altered upon treatment with com-
mon inflammatory mediators (Lalor et al. 2002) and several
groups have studied the expression of VAP-1 in cells that
have been modified to overexpress the protein on their
surface. The recruitment of immune cells was enhanced in
cells overexpressing VAP-1 via a mechanism that was, in
part, dependent on the enzymatic action of VAP-1 (Koskinen
et al. 2004; Salmi et al. 2000).
Until recently, little was known about the cellular dis-
tribution of VAP-1 except that it can be mobilised from
intracellular stores and trafficked to the membrane during
inflammation (Salmi and Jalkanen 2001). Sole et al.
updated this model by creating both an endothelial cell line
from human umbilical vein endothelial cells (HUVEC) and
a smooth muscle cell line (A7r5) that expressed VAP-1 at
high levels (Sole and Unzeta 2011), where the protein was
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observed to associate with lipid rafts and Golgi/endosomal
fractions.
To extend our knowledge of the trafficking of VAP-1,
we expressed a GFP-fusion protein in both endothelial and
stromal cells and used multicolour confocal microscopy to
determine the cellular distribution of VAP-1 and identify
compounds that might affect how the protein is transported
within the cell.
Materials and methods
Human tissue
Human tissue was obtained from the Queen Elizabeth
Hospital (Birmingham, UK) after informed consent and
with local ethics committee approval. Diseased liver tissue
was taken from patients undergoing liver transplantation
for chronic liver disease (CLD) and normal liver from
uninvolved tissue removed at surgical resection for hepatic
colorectal metastases or from surplus donor liver.
Isolation of human activated liver myofibroblasts
(aLMF) and HSEC
aLMF were purified from fibrotic tissue as described pre-
viously (Holt et al. 2009). Cells were plated on plastic in
DMEM/16 % FCS (Invitrogen, UK) and used within four
passages. Liver endothelial cells (HSEC) were isolated
from human liver tissue obtained from explanted livers or
donor tissue surplus to surgical requirements using a col-
lagenase digestion and CD31-positive selection as descri-
bed previously (Lalor et al. 2002). Cells were cultured in
endothelial basal media (Invitrogen, UK) containing 10 %
heat inactivated AB human serum (HD Supplies, Glasgow,
UK), 10 ng/mL vascular endothelial growth factor (VEGF)
and 10 ng/mL hepatocyte growth factor (HGF) (Pepro-
Tech, UK) in rat tail collagen-coated tissue culture flasks.
Cell lines
LX-2, a low serum adapted HSC cell line (Xu et al. 2005),
a kind gift from Scott Friedman (Mount Sinai, New York),
were grown in DMEM supplemented with 2 % FCS. The
human embryonic kidney cell line, HEK293 were obtained
from the European Collection of Cell Cultures (ECACC)
and were cultured in DMEM supplemented with 10 % FCS
and 25 mM HEPES.
Construction of plasmids encoding GFP-fusion proteins
The sequence for VAP-1 was sub-cloned out of a
pcDNA3.1 vector containing the full-length VAP-1
sequence with a GFP tag at the 30-end (wtVAP-1-GFP, a
kind gift from David Smith, Biotie Therapies, Finland) into
the pcDNA6.2N-EmGFP TOPO vector (Life Technolo-
gies) using primers coding for Asn2–Asn763 of the VAP-1
sequence followed by three stop codons (TAG TGA TAA)
to reduce the frequency of read-through errors. The plas-
mid also codes for ampicillin and blasticidin selection,
drives expression of the target protein from a CMV pro-
moter region and provides an 18 amino acid linker region
to connect the GFP moiety to the VAP-1 sequence (GSS
PST SLYK KAG SEFAL). Forward primer: 50-AACCA
GAAGA CAATCCTCGT GCTCCTC-30; reverse primer:
50-TTATCACT AATTGTGAGA GAAGCCCCCG-30. The
orientation and correctness of the insert was confirmed by
sequencing (Functional Genomics Laboratory, University
of Birmingham). A mutation corresponding to a change in
Tyr to Phe at amino acid position 471 (Y471F) which has
been shown to prevent formation of the active site top-
aquinone was introduced using the QuikChange Site
Directed Mutagenesis Kit (Stratagene, UK) and the fol-
lowing primers: forward 50-ATGTCCACCT TGCTCAA
CTT CGACTATGTG TGGGATACGG-30; reverse 50-CC
GTATCCCA CACATAGTCG AAGTTGAGCA AGGTG
GACAT-30. The identity of the mutant was verified by
sequencing and is henceforth referred to as GFP-(Y471F)
VAP-1. A pcDNA6.2N-EmGFP TOPO plasmid containing
the sequence for the cytoplasmic protein chloramphenicol
acetyl transferase (CAT) was used as an expression control
(Invitrogen, UK).
Transfection of cells
Cells were transiently transfected with plasmid DNA using
a Nucleofector II (Lonza, UK) according to the manufac-
turer’s instructions. In brief, 2–10 lg DNA were Nucleo-
fected into 0.5–1.0 9 106 cells in 100 ll Nucleofection
solution (basic primary endothelial cell kit for HSEC,
program T-005; basic primary fibroblast kit for aLMF and
LX-2, program A-023; nucleofector solution V, program
Q-001 for HEK293) and transferred into tissue culture
vessels containing the appropriate media.
Treatment of transfectants with modulators of cellular
trafficking and enzyme function
Cells (0.5 9 106) were Nucleofected with 5 lg DNA,
resuspended in 5 mL media and then aliquotted into each
well of an Ibidi Slide 12 chamber slide (200 lL/well). The
cultures were incubated at 37 C/5 % CO2 overnight after
which the media was replaced with a low-serum-containing
equivalent (endothelial basal media plus 2 % FCS for
HSEC, DMEM containing 2 % FCS for aLMF and LX-2).
At 48 h post-Nucleofection, selected wells were dosed with
952 C. J. Weston et al.
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the following compounds in appropriate media and left to
incubate for 16 h: (a) marimastat, 10 lM (Calbiochem,
UK); (b) bafilomycin A1, 1 lM (Calbiochem, UK);
(c) GolgiPlug (Brefeldin A), 1 lL/mL (BD Biosciences,
UK); (d) Golgistop (Monensin), 0.7 lL/mL (BD Biosci-
ences, UK). The cells were then fixed with 4 % parafor-
maldehyde for 10 min and stored in PBS at 4 C before
being imaged as described above. For live cell staining, the
samples were incubated for 30 min with control antibody
(mouse IgG2a, Dako) or anti-VAP-1 antibody (TK8-14,
BioTie Therapies) at 10 lg/mL prior to fixation as above.
Separate wells were dosed at 72 h post-Nucleofection for
30 min with one of the following compounds: (a) methyl-
amine, 1 mM (Sigma, UK); (b) semicarbazide, 250 lM
(Sigma, UK); (c) cytochalasin D, 10 lM (Calbiochem,
UK); (d) jasplakinolide, 500 nM (Calbiochem, UK);
(e) nocodazole, 10 lM (Calbiochem, UK). The cells were
then fixed with PFA as described above. For washout
studies, wells were dosed with nocodazole for 30 min at
which point the media was changed and the cells were
fixed immediately with 4 % PFA or following a further
incubation of 15 or 30 min in the absence of the inhibitor.
In all cases, appropriate vehicle controls (DMSO or etha-
nol) were monitored in parallel.
Amine oxidase assay
VAP-1 is a semicarbazide-sensitive amine oxidase
(SSAO). Amine oxidase activity of live cells (80,000 cells
per well in a 24 well plate) was measured using a contin-
uous Amplex UltraRed based assay (Molecular Probes,
Invitrogen, UK) according to the manufacturer’s instruc-
tions. Each reaction mix contained monoamine oxidase A
and B inhibitors (clorgyline, pargyline, 200 lM each) and
the artificial VAP-1 substrate benzylamine (1 mM) in the
absence and presence of the SSAO inhibitor 2-bromoeth-
ylamine (200 lM, Sigma).
Fluorescent staining of fixed cells
Fixed cells were permeabilised with 0.3 % Triton-X100 in
PBS and subsequently blocked with 10 % goat serum in
PBS containing 0.1 % Triton-X100. Primary antibodies
raised against specific organelles (mouse-anti-GM130,
mouse-anti-EEA1 from BD Biosciences both at 5 lg/mL;
rabbit-anti-GRP94, 1/100, AbCAM; mouse-anti-LAMP-1,
5 lg/mL, BioLegend), rabbit-anti-GFP (D5.1, Cell Sig-
naling, 1/50) and/or anti-VAP-1 antibody TK8-14 (mouse-
anti-VAP-1, 10 lg/mL, BioTie Therapies) were diluted in
PBS containing 0.1 % Triton-X100 and 2 % goat serum
and added to the cells, and the samples were incubated at
4 C overnight. The cells were washed with PBS/0.1 %
Triton-X100 and incubated with an appropriate Alexa
Fluor conjugated secondary antibody in the same buffer for
1 h at room temperature (1:500 dilution of secondary,
Alexa Fluor-546/Alexa Fluor-633, Invitrogen, UK). The
wells were then washed with PBS/0.1 % Triton-X100,
stained with DAPI and then mounted with Mowiol. Images
were acquired using a Zeiss LSM 510 confocal fluores-
cence microscope (Carl Zeiss, Germany).
Western blot
Total cell protein was isolated using CelLytic M lysis
buffer (Sigma, UK) supplemented with complete ULTRA
protease inhibitors, PhosSTOP phosphatase inhibitors and
DNase I (all Roche Diagnostics, UK) according to the
manufacturer’s instructions. Protein concentration was
determined by bicinchoninic acid assay with BSA as
standard (Sigma, UK). Samples (40 lg/lane for HEK293
and LX-2 lysates, 8 lg/lane for HSEC and aLMF lysates)
were separated on 4 % SDS-PAGE gels, transferred on to
nitrocellulose which were then blocked with 5 % milk
powder in PBS containing 0.05 % Tween-20 (blotting
buffer). The membranes were then incubated with primary
antibody (TK8-14, 2 lg/mL, in blotting buffer) overnight
at 4 C. Proteins were visualised using HRP-conjugated
secondary antibodies (Rabbit-anti-mouse-HRP, 1:2,500 in
blotting buffer, 1 h incubation at room temperature; Dako,
UK) and SuperSignal West Pico chemiluminescent sub-
strate (Pierce, UK). Recombinant VAP-1 (rVAP-1) pro-
duced in CHO, corresponding to the extracellular domain
of VAP-1 (a kind gift from David Smith, Biotie Therapies,
Finland), was used as a positive control.
Results
A VAP-1 GFP-fusion protein expressed by HEK293
was enzymatically active
VAP-1 is predicted to be a type II membrane protein with a
short cytoplasmic tail of four amino acids (NQKT) with no
known signal sequence, and a large extracellular domain
which contains the enzyme active site. To better under-
stand the cellular distribution of VAP-1, we designed a
GFP fusion protein driven from a CMV promoter that
incorporated an 18 amino acid linker connecting the GFP
moiety to the N-terminus of VAP-1 (GFP-wtVAP-1). We
designed a second expression vector in which the tyrosine
at position 471 in the VAP-1 sequence was replaced by
Cellular localization and trafficking of vascular adhesion protein-1 953
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phenylalanine (GFP-(Y471F)VAP-1). This mutation pre-
vents the formation of a topaquinone in the active site and
has been shown to render the enzyme incapable of catalysis
(Jalkanen et al. 2007). We also included a control plasmid-
encoding GFP-tagged chloramphenicol acetyl transferase,
a cytoplasmic protein, driven from the same CMV pro-
moter (GFP-CAT, Invitrogen).
The expression of these constructs in HEK293 cells was
confirmed by western blotting (Fig. 1a) with a transfection
efficiency of [80 % as determined by flow cytometry (data
not shown). The enzyme activity of GFP-wtVAP-1 was
confirmed using benzylamine as a substrate (Fig. 1b). Both
GFP-CAT and GFP-(Y471F)VAP-1 exhibited extremely
low basal levels of activity. A C-terminal GFP-fusion
protein, wtVAP-1-GFP, was also catalytically inactive,
presumably as a result of blockade of the enzyme active
site by the GFP moiety.
GFP-VAP-1 localizes to vesicles in both hepatic
endothelial and stromal cells
To determine the localization of VAP-1 in HSEC, aLMF
and LX-2, cells were transiently transfected with plasmid-
encoding GFP-fusion proteins and visualized by confocal
microscopy. We used Nucleofection-based technology to
deliver the plasmid as the transfection efficiency was low
with traditional lipid-based approaches. We routinely
observed [50 % efficiency of transfection in LX-2 cells,
but the primary cells showed more variability (30–70 %
efficiency); in all cases, the viability following Nucleo-
fection was high ([70 %, data not shown). Figure 2a
demonstrates that in all cell types GFP-wtVAP-1 had a
distinct perinuclear distribution and was concentrated in
numerous vesicles and cell protrusions. Overall, there was
little accumulation of GFP signal on the membrane of the
stromal cells, whereas cell surface GFP staining was more
evident in HSEC (arrows), reflecting the differences in role
for these two cell types: endothelial VAP-1 is involved in
recruitment of leukocytes from flow which would require
surface-bound protein for capture, whereas stromal cells
have little exposure to flow and might not require the
protein to be accessible at the surface of the cell. There
were no macroscopic differences in distribution of the
GFP-wtVAP-1 and GFP-(Y471F)VAP-1 fusion proteins
(Online resource: supplementary Fig. 1), and treatment of
the cells with an amine oxidase substrate, benzylamine, or
inhibitor, semicarbazide, had no effect on the localization
of the proteins (Table 1, Online resource: supplementary
Fig. 2). GFP-CAT was expressed throughout the cytoplasm
in all three cell types studied.
Western blotting of the transfected cells for GFP-VAP-
1 demonstrated that the protein was expressed in both
aLMF and HSEC at similar levels (equal protein loading)
at 240 kDa (Fig. 2b). Increased protein yields were
obtained from transfection of the LX-2 cell line and
analysis of this enriched cell lysate by western blotting
confirmed that the dimeric form predominates over the
monomer, despite the presence of reducing agent during
sample preparation. There was no evidence for cleavage
by proteinases in any of the samples despite stromal cells
being a rich source of these enzymes. Furthermore, the
addition of marimastat, a metalloproteinase inhibitor, had
little effect on the subcellular distribution of the fusion
proteins (Table 1).
Fig. 1 A GFP-wtVAP-1 fusion protein expressed in HEK293 was
enzymatically active a GFP-wtVAP-1 and the enzyme dead mutant
GFP-(Y471F)VAP-1 expressed in HEK293 had a molecular weight of
approximately 115 kDa (predicted 113 kDa) as assessed by western
blot (detection: anti-VAP-1 TK8-14 mAb). This was greater than the
molecular weight of recombinant VAP-1 (rVAP-1, corresponding to
the extracellular domain of VAP-1) due to the presence of the GFP
moiety. There was no VAP-1 detectable in GFP-CAT transfected
cells. b GFP-wtVAP-1 expressed in HEK293 was capable of
deaminating the artificial substrate benzylamine as assessed by
Amplex red assay. An enzyme-dead mutant GFP-(Y471F)VAP-1, the
control protein GFP-CAT and a C-terminal GFP fusion protein,
wtVAP-1-GFP exhibited only very low basal activity (****p \ 0.001
versus GFP-wtVAP-1, one-way analysis of variance with Tukey’s
post test, Graphpad Prism v.6.0a)
954 C. J. Weston et al.
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Fig. 2 A GFP-VAP-1 fusion
protein localized to vesicles in
endothelial cells, fibroblasts and
an hepatic stellate cell line
a GFP-CAT (top panels) and
GFP-wtVAP-1 (lower panels)
fusion proteins produced by
transient transfection of LX-2,
aLMF and HSEC were imaged
using multicolour confocal
microscopy. Nuclei stained with
DAPI are shown in blue. Scale
bar 20 lm b Dimeric GFP-
wtVAP-1 was detected in cell
lysates of LX-2, aLMF and
HSEC using the anti-VAP-1
antibody, TK8-14. Samples for
aLMF and HSEC were loaded at
8 lg/lane and LX-2 at
40 lg/lane
Table 1 Effect of different compounds on the distribution of GFP-wtVAP-1 in different cell types
Compound Action LX-2 aLMF HSEC
Semicarbazide SSAO inhibitor X X X
Methylamine SSAO substrate X X X
Brefeldin A Golgi/endosome inhibitor Majority of GFP signal retained in Golgi
Monensin Golgi inhibitor X X X
Jasplakinolide Actin inhibitor X Minor changes in distribution of GFP signal
Cytochalasin D Actin inhibitor GFP and VAP-1 distribution largely unaffected relative to cell shape. Association with cell
protrusions more pronounced
Nocodzaole Microtubule inhibitor X Minor changes in distribution of GFP signal
Marimastat Metalloproteinase inhibitor X X X
Bafilomycin A1 H ? -ATPase inhibitor Induced co-localization of GFP and anti-VAP-1 signal
‘‘X’’ denotes no gross effect on distribution of GFP signal
Cellular localization and trafficking of vascular adhesion protein-1 955
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GFP-VAP-1 is associated with early endosomes
and lyososomal trafficking
Immunofluorescent staining of organelles within VAP-1
transfected cells was analysed by multicolour confocal
microscopy and revealed that both the wild-type and
enzyme-dead mutant of VAP-1 were expressed in endo-
plasmic reticulum (GRP94), Golgi (GM130) (Online
resource: supplementary Fig. 3 a,b) and early endosomes
(EEA1) (Fig. 3a). Although the majority of the GFP
signal co-localized with staining for VAP-1 (as detected
with anti-VAP-1 antibody), we observed some vesicles in
both stromal and endothelial cells that were low/negative
for GFP, but stained brightly for VAP-1. These vesicles
were present in all fixed cells (arrows; Fig. 3b, lower
panel, and Online resource: supplementary Fig. 4) but
were not detected in cells treated with anti-VAP-1 anti-
body before fixation (Fig. 3b, upper panel). We did not
Fig. 3 GFP-wtVAP-1 localizes
to endosomes and other cellular
vesicles. a Multicolour confocal
microscopy indicated that GFP-
wtVAP-1 co-localized with the
early endosomal marker EEA-1.
Merged images: GFP green;
EEA-1 red; VAP-1 blue; nuclei
white. b The distribution of GFP
and anti-VAP-1 antibody
fluorescence in live and fixed
cells revealed the presence of
intracellular GFPlowVAP-1high
vesicles in fixed, but not live
cells. Merged images: GFP
green; VAP-1 red; nuclei blue.
Scale bar 20 lm
956 C. J. Weston et al.
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Fig. 3 continued
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observe any non-specific uptake of an isotype matched
control in GFP-wtVAP-1 transfected cells or any similar
staining pattern in those cells that had been transfected
with GFP-CAT (data not shown). Staining of LX-2 cells
with an antibody raised against GFP showed that while
the intrinsic GFP fluorescence signal was diminished
in these vesicles the GFP moiety had not been lost
(co-localization with VAP-1 staining, Online resource:
supplementary Fig. 5). This suggested that there might be
a mechanism whereby the fluorescence of the GFP is
quenched in these vesicles.
Incubation of the cells with the protein transport inhib-
itor brefeldin A prevented the export of GFP-wtVAP-1
from the ER/Golgi, whereas monensin had very little effect
(Table 1 and data not shown). It is known that brefeldin A
can affect the formation of endosomes in addition to tar-
geting the Golgi apparatus and this might explain the dif-
ferences observed between these two inhibitors. The
addition of bafilomycin, which inhibits vacuolar-type H?-
ATPase driven acidification of endosomes and lysosomes
(Bowman et al. 1988), resulted in an accumulation of GFP
signal in vesicles that also stained positive for VAP-1
(Fig. 4a). Vehicle controls (DMSO or ethanol) at equiva-
lent concentrations had no effect. Using LAMP-1 as a
lysosomal marker we showed that in the absence of
bafilomycin, VAP-1 could be detected in lysosomes via
antibody binding, but the corresponding GFP signal was
absent (Fig. 4b, top panels). However, upon the addition of
bafilomycin the GFP signal overlapped with that of LAMP-
1 and VAP-1 (Fig. 4b, lower panels) suggesting that the
low pH of recycling vesicles quenches the GFP signal
associated with GFP-wtVAP-1 (but does not disrupt the
interaction with the anti-VAP-1 antibody), giving rise to
GFPlow VAP-1high vesicles (Figs. 3 , 4). Upon treatment
with bafilomycin, the rise in pH in these vesicles due to
inhibition of the H? -ATPase establishes an environment
in which GFP fluorescence is maintained, leading to
complete co-localization of the GFP and VAP-1 fluorescent
signals. This effect of bafilomycin was absent in cells
expressing GFP-CAT (data not shown) suggesting that the
redistribution was not due to a toxic effect of the
compound.
The addition of cytochalasin D to disrupt the actin
cytoskeleton altered the cell morphology and enhanced the
association of both GFP and VAP-1 signals with cell pro-
jections (Fig. 4c). The effects of other inhibitors are sum-
marised in Table 1. Supplementation of the media with
jasplakinolide which stabilizes actin filaments had no
detectable effect on the distribution of VAP-1, and desta-
bilization of microtubules by nocodazole had little effect
on the distribution of the GFP-proteins or total VAP-1 at
the concentrations used in this study (data not shown).
Discussion
We have shown that a fusion protein where a GFP moiety
is linked to the N-terminus of VAP-1 can be expressed in
endothelial and stromal cells and retain its catalytic activ-
ity. The fusion protein was monomeric under denaturing
conditions in HEK293 whole cell lysates, whereas the
dimeric form predominated in lysates prepared from
transfected endothelial and stromal cells (Figs. 1, 2). The
reasons for this are not yet clear as the lysates were pre-
pared under the same conditions. The dimer interface is
formed by opposing D4 domains of each of the VAP-1
monomers including an inter-subunit disulfide bond
between opposing Cys748 residues (Airenne et al. 2005).
Changes in glycosylation of the protein, the presence of
previously undescribed binding partners or orientation of
the transmembrane domain might protect the dimer from
dissociation some cell types. It is unlikely that this effect
was due to multimerization of the GFP moiety as we used
EmGFP that has a low propensity to dimerize (Shaner et al.
2007).
GFP-wtVAP-1 showed some membranous staining, but
was mainly distributed throughout the cytoplasm associ-
ated with subcellular vesicles via a mechanism that is
independent of enzyme activity. These data are consistent
with those obtained for endothelial and smooth muscle cell
lines where untagged VAP-1 was shown to have both a
cytosolic distribution and an association with flotillin-
containing lipid rafts (Sole and Unzeta 2011). This may
allow the protein to be mobilised rapidly during inflam-
mation as has been demonstrated previously for endothe-
lial cells (Salmi and Jalkanen 2001), possibly via
association with the actin cytoskeleton as a treatment of
the cells with cytochalasin D disrupted the trafficking of
GFP-wtVAP-1.
A proportion of the VAP-1-positive vesicles were neg-
ative/weak for GFP. Our data suggest that GFP-VAP-1
fusion protein that is being degraded or subjected to
reuptake at the membrane into vesicles experiences a low
pH environment in which the fluorescence of the GFP
moiety is quenched (pKa of EmGFP is approximately 6.0;
the pH of lysosomes is around pH 4.5)(Patterson et al.
1997). This would be advantageous in live cell imaging
techniques, where the trafficking of newly synthesised
GFP-VAP-1 protein can be studied without the complica-
tion of protein that has been targeted for degradation.
958 C. J. Weston et al.
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Fig. 4 Treatment of cells with bafilomycin, and staining for LAMP-1
revealed that GFP-wtVAP-1 localizes within vesicles of low pH a In
the presence of bafilomycin A1 (1 lM), the GFP and VAP-1 signals
from GFP-wtVAP-1 showed greater co-localization when compared
with vehicle treated controls. There was no difference in the
distribution of GFP signal in GFP-CAT transfected cells (data not
shown). Merged images: GFP green; VAP-1 red; nuclei blue.
b Lysosomal-associated membrane protein-1 (LAMP-1) co-localized
with anti-VAP-1 staining in both vehicle and bafilomycin A1 treated
HSEC, whereas an overlap with the GFP signal was only seen in the
bafilomycin A1 treated cells. Merged images: GFP/VAP-1 green;
LAMP-1 red; nuclei blue. c Cytochalasin D (10 lM), a disruptor of
the actin cytoskeleton, altered the distribution of VAP-1 with the
greatest effect observed in HSEC. Scale bar 20 lm
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